TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Status:
Enrolling by invitation
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE
combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment
will continue until the death or intolerable toxicity or patients withdrawal of consent,and
the target sample size is 54 individuals.